GeNeuro’s Temelimab Phase IIa Data in Type 1 Diabetes at 12 Months Confirms RAINBOW Positive Results
Study meets objective of demonstrating safety and pharmacodynamic response Confirmed excellent safety profile in combination with concomitant medications, with no serious adverse events Opens way for further de ...